Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Valacyclovir].

M Biernat-Sudolska1

  • 1Zakładu Wirusologii, Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie.

Przeglad Lekarski
|April 27, 1999
PubMed
Summary
This summary is machine-generated.

Valaciclovir, a prodrug of Aciclovir, shows promise in clinical studies for treating herpes virus infections. Research details its antiviral activity, pharmacokinetics, and clinical efficacy in various patient groups.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concomitant infections with human papillomavirus and various mycoplasma and ureaplasma species in women with abnormal cervical cytology.

Advances in medical sciences·2011
See all related articles

Area of Science:

  • Virology
  • Pharmacology
  • Clinical Medicine

Background:

  • Aciclovir is a key antiviral medication.
  • Valaciclovir is an orally administered prodrug of Aciclovir.
  • Clinical evaluation of Valaciclovir is ongoing.

Purpose of the Study:

  • To present the antiviral activity and pharmacokinetic properties of Valaciclovir.
  • To discuss the clinical efficacy of Valaciclovir in herpes virus infections.

Main Methods:

  • Review of animal studies on Valaciclovir.
  • Analysis of pharmacokinetic data in immunocompetent and immunosuppressed patients.
  • Assessment of clinical efficacy in herpes virus infection cases.

Main Results:

Related Experiment Videos

  • Valaciclovir exhibits significant antiviral activity.
  • Pharmacokinetic profiles were evaluated in diverse patient populations.
  • Clinical efficacy data in herpes virus infections are presented.

Conclusions:

  • Valaciclovir demonstrates favorable pharmacokinetic properties and antiviral activity.
  • Clinical efficacy supports its use in herpes virus infections.
  • Further clinical studies are warranted for Valaciclovir.